R&D Pipeline
Our research focuses on developing a broad portfolio of drug candidates across areas of significant unmet needs. The programs in our portfolio are derived from our profound scientific and clinical expertise and are currently at various stages of preclinical and clinical developments. We are committed to advancing our programs and expanding our portfolio with an end goal of potentially providing therapies to patients in need.
Our research focuses on developing a broad portfolio of drug candidates across areas of significant unmet needs. The programs in our portfolio are derived from our profound scientific and clinical expertise and are currently at various stages of preclinical and clinical developments. We are committed to advancing our programs and expanding our portfolio with an end goal of potentially providing therapies to patients in need.
Neurodegenerative Diseases
c-Abl
Parkinson, ALS
c-Abl/LRRK2
ALS, Parkinson
c-Abl/PET
PET tracer for c-Abl therapeutic
Undisclosed
Parkinson, Alzheimer, ALS

Undisclosed
Parkinson

Oncology
HPK1
Immuno-oncology
A2aR
Immuno-oncology
Undisclosed
Immuno-oncology
Rare Diseases
Undisclosed
Rett syndrome and other genetic diseases
Platform Technology
GeniFiNDTM
1ST-401
Genomic-based target discovery platform for neurodegenerative diseases
